Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC
Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
Seeking Alpha / 1 hour from now 1 Views
Seeking Alpha / 1 hour from now 1 Views
Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC
Comments